Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-02-14

FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Supplemental Application (Lannett Company, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for lisdexamfetamine dimesylate (generic) from Lannett Company, Inc., enabling a new generic product entry.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LISDEXAMFETAMINE DIMESYLATE (Lisdexamfetamine dimesylate)

Snippet

SUPPL AP for LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)